Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.

You may also be interested in...



Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market

Victrelis' final European approval means that Merck & Co. has its nose in front of rival Vertex for the time being.

Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market

Victrelis' final European approval means that Merck & Co. has its nose in front of rival Vertex for the time being.

Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week

Merck will begin shipping Victrelis (boceprevir) to pharmacies within a week, the company announced following FDA approval of the hepatitis C drug after market-close on May 13 – a time-frame that roughly coincides with expected FDA action on Vertex's Incivek (telaprevir).

Related Content

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel